Podcasts about Elekta

A conversation with Dr. Shweta Kedia Thank you to Elekta for sponsoring this conversation!

A conversation with Dr. Eduardo Lovo Thank you to Elekta for sponsoring this conversation

This podcast is sponsored by Elekta

Anna Blixt, manager och konsult på Deloitte, med erfarenhet av roller som Global Head of Employer Branding hos stora aktörer som Elekta och Fiskars, delar i detta avsnitt med Louise Thulin och Josefin Malmer med sig av sina bästa tips för att få samman EB och TA på ett bra sätt.

Dr. Neeraj Agarwal and Dr. Peter Hoskin discuss key abstracts in GU cancers from the 2025 ASCO Genitourinary Cancers Symposium, including novel therapies in prostate, bladder, and kidney cancer and the impact of combination therapies on patient outcomes. TRANSCSRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I'm Dr. Neeraj Agarwal, the director of the Genitourinary Oncology Program and professor of medicine at the Huntsman Cancer Institute at the University of Utah, and editor-in-chief of ASCO Daily News. Today, we'll be discussing practice-informing abstracts and other key advances in GU oncology featured at the 2025 ASCO Genitourinary Cancers Symposium. Joining me for this discussion is Dr. Peter Hoskin, the chair of this year's ASCO GU Symposium. Dr. Hoskin is a professor in clinical oncology in the University of Manchester and honorary consultant in clinical oncology at the Christie Hospital, Manchester, and University College Hospital London, in the United Kingdom. Our full disclosures are available in the transcript of this episode. Peter, thank you for joining us today. Dr. Peter Hoskin: Thank you so much, Neeraj. I am very pleased to be here. Dr. Neeraj Agarwal: The GU meeting highlighted remarkable advancements across the spectrum of GU malignancies. What stood out to you as the most exciting developments at the ASCO GU Symposium?  Dr. Peter Hoskin: The theme of this year's meeting was "Driving Innovation, Improving Patient Care," and this reflected ASCO GU's incredible milestone in GU cancer research over the years. We were thrilled to welcome almost 6,000 attendees on this occasion from over 70 countries, and most of them were attending in person and not online, although this was a hybrid meeting. Furthermore, we had more than 1,000 abstract submissions. You can imagine then that it fostered fantastic networking opportunities and facilitated valuable knowledge and idea exchanges among experts, trainees, and mentees. So, to start I'd like to come back to you for a second because the first day started with a focus on prostate cancer and some of the key clinical trials. And congratulations to you, Neeraj, on sharing the data from the TALAPRO-2 trial, which we were eagerly awaiting. I'd love to get your thoughts on the data that you presented. Could you tell us more about that trial, Abstract LBA18?  Dr. Neeraj Agarwal: Yes, Peter, I agree with you. It was such an exciting conference overall and thank you for your leadership of this conference. So, let's talk about the TALAPRO-2 trial. First of all, I would like to remind our audience that the combination of talazoparib plus enzalutamide was approved by the U.S. FDA in June 2023 in patients with metastatic castration-resistant prostate cancer harboring HRR gene alterations, after this combination improved the primary endpoint of radiographic progression-free survival compared to enzalutamide alone in the randomized, double-blind, placebo-controlled, multi-cohort phase 3 TALAPRO-2 trial. In the abstract I presented at ASCO GU 2025, we reported the final overall survival data, which was a key alpha-protected secondary endpoint in cohort 1, which enrolled an all-comer population of patients with mCRPC. So, at a median follow-up of around 53 months, in the intention-to-treat population, the combination of talazoparib plus enzalutamide significantly reduced the risk of death by 20% compared to enzalutamide alone, with a median OS of 45.8 months in the experimental arm versus 37 months in the control arm, which was an active control arm of enzalutamide. This improvement was consistent in patients with HRR alterations with a hazard ratio of 0.54 and in those with non-deficient or unknown HRR status, with a hazard ratio of 0.87. In a post hoc analysis, the hazard ratio for OS was 0.78 favoring the combination in those patients who did not have any HRR gene alteration in their tumors by both tissue and ctDNA testing. Consistent with the primary analysis, the updated rPFS data also favored the experimental arm with a median rPFS of 33.1 compared to 19.5 months in the control arm, and a hazard ratio of 0.667. No new safety signals were identified with extended follow-up. Thus, TALAPRO-2 is the first PARP inhibitor plus ARPI study to show a statistically significant and a clinically meaningful improvement in OS compared to standard-of-care enzalutamide as first-line treatment in patients with mCRPC unselected for HRR gene alterations. Dr. Peter Hoskin: Thank you, Neeraj. That's a great summary of the data presented and very important data indeed. There was another abstract also featured in the same session, Abstract 20, titled “Which patients with metastatic hormone-sensitive prostate cancer benefit more from androgen receptor pathway inhibitors? STOPCAP meta-analyses of individual participant data.” Neeraj, could you tell us more about this abstract? Dr. Neeraj Agarwal: Absolutely, I would be delighted to. So, in this meta-analysis, Dr. David Fischer and colleagues pooled individual participant data from different randomized phase 3 trials in the mHSPC setting to assess the potential ARPI effect modifiers and determine who benefits more from an ARPI plus ADT doublet. The primary outcome was OS for main effects and PFS for subgroup analyses. Prostate cancer specific survival was a sensitivity outcome. The investigators pooled data from 11 ARPI trials and more than 11,000 patients. Overall, there was a clear benefit of adding an ARPI on both OS and PFS, with hazard ratios of 0.66 and 0.51, respectively, representing a 13% and 21% absolute improvement at 5 years, respectively, with no clear difference by the class of agent. When stratifying the patients by age group, the effects of adding an ARPI on OS and PFS were slightly smaller in patients older than 75, than in those younger than 65, or aged between 65 and 75 years. Notably, in the trials assessing the use of abiraterone, we saw very little OS effects in the group of patients older than 75, however there was some benefit maintained in prostate-cancer specific survival, suggesting that other causes of death may be having an impact. The effects of the other ARPIs, or ‘lutamides' as I would call them, were similar across all three age subgroups on both OS and PFS. Therefore, the majority of patients with mHSPC benefit from the addition of ARPIs, and the benefits/risks of abiraterone and other ‘amides' must be considered in older patients.  Dr. Peter Hoskin: Thanks, Neeraj. Another great summary relevant to our day-to-day practice. Of course, there's ongoing collection of individual patient data from other key trials, which will allow robust comparison of ARPI doublet with triplet therapy (including docetaxel), guiding more personalized treatment.   Dr. Neeraj Agarwal: I agree with you, Peter, we need more data to help guide personalized treatment for patients with mHSPC and potentially guide de-escalation versus escalation strategies. Now, moving on to a different setting in prostate cancer, would you like to mention Abstract 17 titled, “Overall survival and quality of life with Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901),” presented by Dr. Louise Emmett? Dr. Peter Hoskin: Of course I will. So, ENZA-p was a multicenter, open-label, randomized, phase 2 trial conducted in Australia. It randomized 163 patients into adaptive doses (2 or 4 cycles) of Lu-PSMA-617 plus enzalutamide versus enzalutamide alone as first-line treatment in PSMA-PET-CT-positive, poor-risk, mCRPC. The interim analysis of ENZA-p with median follow-up 20 months showed improved PSA-progression-free survival with the addition of Lu-PSMA-617 to enzalutamide. Here, the investigators reported the secondary outcomes, overall survival, and health-related quality of life (HRQOL). After a median follow up of 34 months, overall survival was longer in the combination arm compared to the enzalutamide arm, with a median OS of 34 months compared to 26 months; with an HR of 0.55. Moreover, the combination improved both deterioration-free survival and health-related quality of life indicators for pain, fatigue, physical function, and overall health and quality of life compared to the control arm. Consistent with the primary analysis, the rPFS also favored the experimental arm with a median rPFS of 17 months compared to 14 months with a HR of 0.61. So, the addition of LuPSMA improved overall survival, and HRQOL in patients with high-risk mCRPC. Dr. Neeraj Agarwal: Thank you, Peter. Great summary, and promising results with Lu-177 and ARPI combination in first line treatment for mCRPC among patients who had two or more high risk features associated with early enzalutamide failure. Before we move on to bladder cancer, would you like to tell us about Abstract 15 titled, “World-wide oligometastatic prostate cancer (omPC) meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): An analysis from the X-MET collaboration,” presented by Dr. Chad Tang?  Dr. Peter Hoskin: Sure. So, with metastatic-directed therapy (MDT), we have a number of phase 2 studies making up the database, and the X-MET collaboration aimed to consolidate all randomized data on oligometastatic solid tumors. This abstract presented pooled individual patient data from all the published trials involving patients with oligometastatic prostate cancer who received MDT alongside standard of care (SOC) against SOC alone. The analysis included data from five trials, encompassing 472 patients with oligometastatic prostate cancer, and followed for a median of 41 months. Patients were randomly assigned in a 1:1 ratio to receive either MDT plus SOC or SOC alone. The addition of MDT significantly improved PFS. The median PFS was 32 months with MDT compared to 14.9 months with SOC alone, with an HR of 0.45. Subgroup analyses further confirmed the consistent benefits of MDT across different patient groups. Regardless of factors like castration status, receipt of prior primary treatment, stage, or number of metastases, MDT consistently improved PFS. In patients with mHSPC, MDT significantly delayed the time to castration resistance by nine months, extending it to a median of 72 months compared to 63 months in the SOC group with an HR of 0.58. In terms of OS, the addition of MDT improved the 48-month survival rate by 12%, with OS rates of 87% in the MDT+SOC group compared to 75% in the SOC alone group. Dr. Neeraj Agarwal: Thank you, Peter. These data demonstrate that adding MDT to systemic therapy significantly improves PFS, rPFS, and castration resistance-free survival, reinforcing its potential role in the treatment of oligometastatic prostate cancer. So, let's switch gears to bladder cancer and start with Abstract 658 reporting the OS analysis of the CheckMate-274 trial. Would you like to tell us about this abstract?  Dr. Peter Hoskin: Yes, sure, Neeraj. This was presented by Dr. Matt Milowsky, and it was additional efficacy outcomes, including overall survival, from the CheckMate-274 trial which evaluated adjuvant nivolumab versus placebo in patients with high-risk muscle-invasive bladder cancer after radical surgery. The phase 3 trial previously demonstrated a significant improvement in disease-free survival with nivolumab. With a median follow-up of 36.1 months, disease-free survival was longer with nivolumab compared to placebo across all patients with muscle-invasive bladder cancer, reducing the risk of disease recurrence or death by 37%. Among patients who had received prior neoadjuvant cisplatin-based chemotherapy, nivolumab reduced this risk by 42%, whilst in those who had not received chemotherapy, the risk was reduced by 31%. Overall survival also favored nivolumab over placebo, reducing the risk of death by 30% in all patients with muscle-invasive bladder cancer and by 52% in those with tumors expressing PD-L1 at 1% or higher. Among patients who had received prior neoadjuvant chemotherapy, nivolumab reduced the risk of death by 26%, whilst in those who had not received chemotherapy, the risk was reduced by 33%. Alongside this, the safety profile remained consistent with previous findings. Dr. Neeraj Agarwal: Thank you, Peter, for such a nice overview of this abstract. These results reinforce adjuvant nivolumab as a standard of care for high-risk muscle-invasive bladder cancer, offering the potential for a curative outcome for our patients. Dr. Peter Hoskin: I agree with you Neeraj. Perhaps you would like to mention Abstract 659 titled, “Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA.” Dr. Neeraj Agarwal: Of course. Dr. Galsky presented additional outcomes from the phase 3 NIAGARA study, which evaluated perioperative durvalumab combined with neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer. The study previously demonstrated a significant improvement in event-free survival and overall survival with durvalumab compared to chemotherapy alone, with a manageable safety profile and no negative impact on the ability to undergo radical cystectomy. Among the 1,063 randomized patients, those who received durvalumab had a 33% reduction in the risk of developing distant metastases or death and a 31% reduction in the risk of dying from bladder cancer compared to those who received chemotherapy alone. More patients who received durvalumab achieved a pathological complete response at the time of surgery with 37% compared to 28% in the chemotherapy-alone group. Patients who achieved a pathological complete response had better event-free survival and overall survival compared to those who did not. In both groups, durvalumab provided additional survival benefits, reducing the risk of disease progression or death by 42% and the risk of death by 28% in patients with a pathological complete response, while in those patients without a pathological complete response, the risk of disease progression or death was reduced by 23% and the risk of death by 16% when durvalumab was added to the chemotherapy. Immune-mediated adverse events occurred in 21% of patients in the durvalumab group compared to 3% in the chemotherapy-alone group, with grade 3 or higher events occurring in 3% compared to 0.2%. The most common immune-related adverse events included hypothyroidism in 10% of patients treated with durvalumab compared to 1% in the chemotherapy-alone group, and hyperthyroidism in 3% versus 0.8%. At the time of the data cutoff, these adverse events had resolved in 41% of affected patients in the durvalumab group and 44% in the chemotherapy-alone group. Dr. Peter Hoskin: Thank you, Neeraj, for the great summary. These findings further support the role of perioperative durvalumab as a potential standard of care for patients with muscle-invasive bladder cancer. Dr. Neeraj Agarwal: I concur with your thoughts, Peter. Before wrapping up the bladder cancer section, would you like to mention Abstract 664 reporting updated results from the EV-302 trial, which evaluated enfortumab vedotin in combination with pembrolizumab compared to chemotherapy as first-line treatment for patients with previously untreated locally advanced or metastatic urothelial carcinoma? Dr. Peter Hoskin: Yes, of course. Dr. Tom Powles presented updated findings from the EV-302 study, and in this abstract presented 12 months of additional follow-up for EV-302 (>2 y of median follow-up) and an exploratory analysis of patients with confirmed complete response (cCR). The study had a median follow-up of 29.1 months and previously demonstrated significant improvements in progression-free survival and overall survival with enfortumab vedotin and pembrolizumab. This is now the standard of care in global treatment guidelines. Among the 886 randomized patients, enfortumab vedotin and pembrolizumab reduced the risk of disease progression or death by 52% and the risk of death by 49% compared to chemotherapy. The survival benefit was consistent regardless of cisplatin eligibility or the presence of liver metastases. The confirmed objective response rate was higher with enfortumab vedotin and pembrolizumab at 67.5% compared to 44.2% with chemotherapy. The median duration of response was 23.3 months with enfortumab vedotin and pembrolizumab compared to 7.0 months with chemotherapy. A complete response was achieved in 30.4% of patients in the enfortumab vedotin and pembrolizumab group compared to 14.5% in the chemotherapy group, with the median duration of complete response not yet reached in the enfortumab vedotin and pembrolizumab group compared to 15.2 months in the chemotherapy group. Severe treatment-related adverse events occurred in 57.3% of patients treated with enfortumab vedotin and pembrolizumab compared to 69.5% in the chemotherapy group, while in patients who achieved a complete response, severe adverse events occurred in 61.7% of those treated with enfortumab vedotin and pembrolizumab compared to 71.9% with chemotherapy. Treatment-related deaths were reported in 1.1% of patients treated with enfortumab vedotin and pembrolizumab compared to 0.9% with chemotherapy, with no treatment-related deaths occurring in those who achieved a complete response. These findings clearly confirm the durable efficacy of enfortumab vedotin and pembrolizumab, reinforcing its role as the standard of care for the first-line treatment of patients with locally advanced or metastatic urothelial carcinoma, and no new safety concerns have been identified. Dr. Neeraj Agarwal: Thank you for this great summary. Moving on to kidney cancer, let's talk about Abstract 439 titled, “Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate-9ER trial.” Dr. Peter Hoskin: Sure. Dr. Motzer presented the final results from the phase 3 CheckMate-9ER trial, which compared the combination of cabozantinib and nivolumab against sunitinib in previously untreated advanced renal cell carcinoma. The data after more than five years follow-up show that the combination therapy provided sustained superior efficacy compared to sunitinib. In terms of overall survival, we see an 11-month improvement in median OS, 46.5 months for the cabo-nivo versus 35.5 months for sunitinib and a 42% reduction in the risk of disease progression or death, with median progression-free survival nearly doubling – that's 16.4 months in the combination group and 8.3 months with sunitinib. Importantly, the safety profile was consistent with the known safety profiles of the individual medicines, with no new safety concerns identified. Dr. Neeraj Agarwal: Great summary, Peter. These data further support the efficacy of cabo-nivo combination therapy in advanced renal cell carcinoma, which is showing a 11-month difference in overall survival. Dr. Peter Hoskin: Neeraj, before wrapping up this podcast, would you like to tell us about Abstract 618? This is titled “Prospective COTRIMS (Cologne trial of retroperitoneal lymphadenectomy in metastatic seminoma) trial: Final results.” Dr. Neeraj Agarwal: Sure, Peter. I would be delighted to. Dr Heidenrich from the University of Cologne in Germany presented the COTRIMS data evaluating retroperitoneal LN dissection in patients with clinical stage 2A/B seminomas. Seminomas are classified as 2A or B when the disease spreads to the retroperitoneal lymph nodes of up to 2 cm (CS IIA) or of more than 2 cm to up to 5 cm (CS 2B) in maximum diameter, respectively. They account for 10-15% of seminomas and they are usually treated with radiation and chemotherapy. However, radiation and chemo can be associated with long-term toxicities such as cardiovascular toxicities, diabetes, solid cancers, leukemia, particularly for younger patients. From this standpoint, Dr Heidenrich and colleagues evaluated unilateral, modified template, nerve-sparing retroperitoneal lymph node dissection as a less toxic alternative compared to chemo and radiation. They included 34 patients with negative AFP, beta-HCG, and clinical stage 2A/B seminomas. At a median follow-up of 43.2 months, the trial demonstrated great outcomes: a 99.3% treatment-free survival rate and 100% overall survival, with only four relapses. Antegrade ejaculation was preserved in 88% of patients, and severe complications such as grade 3 and 4 were observed in 12% of patients. Pathological analysis revealed metastatic seminoma in 85% of cases, with miR371 being true positive in 23 out of 24 cases and true negative in 100% of cases. It appears to be a valid biomarker for predicting the presence of lymph node metastases. These findings highlight retroperitoneal lymph node dissection is feasible; it has low morbidity, and excellent oncologic outcomes, avoiding overtreatment in 80% of patients and sparing unnecessary chemotherapy or radiotherapy in 10-15% of cases. Dr. Peter Hoskin: Great summary and important data on retroperitoneal lymphadenectomy in metastatic seminoma. These findings will help shape clinical practice. Any final remarks before we conclude today's podcast? Dr. Neeraj Agarwal: Before wrapping up this podcast, I would like to say that we have reviewed several abstracts addressing prostate, bladder, kidney cancers, and seminoma, which are impacting our medical practices now and in the near future. Peter, thank you for sharing your insights with us today. These updates are undoubtedly exciting for the entire GU oncology community, and we greatly appreciate your valuable contribution to the discussion and your leadership of the conference. Many thanks. Dr. Peter Hoskin: Thank you, Neeraj. Thank you for the opportunity to share this information more widely. I'm aware that whilst we have nearly 6,000 delegates, there are many other tens of thousands of colleagues around the world who need to have access to this information. And it was a great privilege to chair this ASCO GU25. So, thank you once again, Neeraj, for this opportunity to share more of this information that we discussed over those few days. Dr. Neeraj Agarwal: Thank you, Peter. And thank you to our listeners for joining us today. You will find links to the abstracts discussed today on the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.  Find out more about today's speakers:   Dr. Neeraj Agarwal    @neerajaiims    Dr. Peter Hoskin Follow ASCO on social media:      @ASCO on Twitter      ASCO on Bluesky  ASCO on Facebook      ASCO on LinkedIn      Disclosures: Dr. Neeraj Agarwal: Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas Dr. Peter Hoskin: Research Funding (Institution): Varian Medical Systems, Astellas Pharma, Bayer, Roche, Pfizer, Elekta, Bristol Myers  

Är fredagens succénotering av Apotea början på en ny vår för konsumentrelaterade aktier på Stockholmsbörsen? Stefan Roos, förvaltare på Origo fonder och Johan Eliasson, Kepler Cheuvreux diskuterar Apotea, Electrolux, Dometic, XXL, Hexagon och Elekta.

We sat down with the Head of Product Security at LivaNova, the former Chief Product Security Officer at Elekta and co-chair of the Legacy Devices Task Group at the Health Sector Coordinating Council to discuss what he learned throughout his long and successful career and to gain insights on regulations, security activities and more

How one of the world's largest medical device makers is using a new strategic narrative to differentiate its software offerings from those of its biggest competitor.

In this episode, host Shikha Jain, MD, speaks with Annmarie Ison about developing safe and accurate software, how software can improve health care disparities and more. •    Welcome to another exciting episode of Oncology Overdrive 0:14 •    About Ison 0:25 •    The interview 1:10 •    Tell me about how you got into this space […] Can you explain what software development is?  1:34 •    What is Elekta and what does the company do?  10:24 •    How do you feel that this type of innovation is transforming cancer care and treating oncology patients? 13:19 •    How is Elekta and its services helping to address health care disparities? 19:32 •    Where do you think AI fits into the bigger picture of the cancer care landscape?  24:53 •    If someone could only listen to the last few minutes of this episode, what would you want them to take away? 28:29 •    How to contact Ison 30:25 •    Thanks for listening 31:05 Annmarie Ison is head of customer service for the software business line at Elekta. She has over 25 years of experience as a software development professional, specializing in product development and software architecture for information management systems and radiation therapy delivery devices. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Ison can be reached via email annmarie.ison@elekta.com or via LinkedIn.  Disclosures: Jain and Ison report no relevant financial disclosures. 

Idag besöker EFN Börslunch Paretos hälsovårdskonferens för att ta pulsen på sektorn. Vad som skiljer olika grupper inom hälsovård är en programpunkt. Bolag som Sobi, Elekta och Xvivo står också på menyn i en diskussion med Paretos analytiker Filip Wiberg och förvaltaren Jannis Kitsakis på AP4. Programledare är Kelly Connelin och Jesper Norberg.

Det är fredag den 13:e september och i Börslunch pratar vi om backtrading, kursras, vinstvarningar, konsumentbolag och medtech. Vi avhandlar bolag som Dustin, Yubico, Ratos, Husqvarna, Norva24, Byggmax, Moberg Pharma och Elekta. Gäster är Stefan Roos från Origo Fonder och Peter Lindvall från Kavaljer. Programledare: Jesper Norberg och Kelly Connelin 

Börslunch snackar småbolag och rapporterande bolag. Norskt förvaltarbesök i form av Hans-Marius Lee Ludvigsen från DNB sätter färg på dagens rapporter. Det ser ut att gå mot strålande tider för Elekta, vi tar upp hoppet i svensk gaming och noterar avhoppet i Hemnet.   Programledare: Gabriel Mellqvist

Vitvarubolaget Electrolux grundades 1919 genom sammanslagningen av två bolag. Drygt hundra år har gått sedan dess och mycket har hänt. Bland annat har Electrolux ynglat av sig bolagen Husqvarna och Electrolux Professional. I    dagens Börslunch tar vi oss en närmare titt på dessa tre bolag. Ett bolag som lever på att sälja den typ av produkter som Electrolux tillverkar är Clas Ohlson. Bolaget har kommit med kvartalsrapport i dag och aktien rusar på börsen. Detta analyseras också i dagens program. Liksom rapporterna från Elekta och Sectra. Fredrik Skoglund, förvaltare på FE Fonder och Johan Eliasson, analytiker på Kepler Cheuvreux, resonerar i programmet om varför Electrolux aktie har haft en dyster utveckling och vad som skulle kunna få det att vända uppåt.   Aktien har gått sämre än börsen varje år sedan 2018. Husqvarna levererade ett starkt resultat det första kvartalet men även för detta bolag har aktieutvecklingen på några års sikt inte imponerat.   Vad det krävs för att kursen långsiktigt ska vända uppåt diskuterar vi i dagens program. Medan Electrolux kämpar vidare med låga marginaler och vikande marknadsandelar så lever Electrolux Professional – som knoppades av 2020 – tämligen gott på storkök, tvättstugor och restauranger. Det är dagens sista samtalsämne.   Programledare: Jonas Malmborg och Gabriel Mellqvist

A conversation with Dr. Dheerendra Prasad. Thank you to Elekta for sponsoring this episode! Find the Gamma Knife online at https://www.elekta.com/products/stereotactic-radiosurgery/elekta-esprit/patients-at-the-center/

A conversation with Dr. Jean Regis. Thank you to Elekta for sponsoring this episode! Find the Gamma Knife online at https://www.elekta.com/products/stereotactic-radiosurgery/elekta-esprit/patients-at-the-center/

Annmarie Ison, Vice President and Head of Service at Elekta, share her remarkable career focusing on life-saving medical technology. Annmarie reflects on her initial aspiration to be a doctor, her pivot to physics, and the serendipitous turn that led her to a startup revolutionizing radiation oncology. With a personal touch, she shares insights from her childhood fascination with science, her transition from aerospace to the dynamic world of Silicon Valley startups, and her commitment to improving patient care through technology. The conversation not only showcases Annmarie's technical expertise but also her deep passion for making a tangible difference in people's lives. Guest links: https://www.elekta.com/ | https://www.elekta.com/products/oncology-informatics/elekta-one/ Interested in being a guest on the show or have feedback to share? Email us at podcast@velentium.com.  PRODUCTION CREDITS Host: Lindsey Dinneen Editing: Marketing Wise Producer: Velentium   EPISODE TRANSCRIPT Episode 029 - Annmarie Ison [00:00:00] Lindsey Dinneen: Hi, I'm Lindsey and I'm talking with MedTech industry leaders on how they change lives for a better world. [00:00:09] Diane Bouis: The inventions and technologies are fascinating and so are the people who work with them. [00:00:15] Frank Jaskulke: There was a period of time where I realized, fundamentally, my job was to go hang out with really smart people that are saving lives and then do work that would help them save more lives. [00:00:28] Diane Bouis: I got into the business to save lives and it is incredibly motivating to work with people who are in that same business, saving or improving lives. [00:00:38] Duane Mancini: What better industry than where I get to wake up every day and just save people's lives. [00:00:42] Lindsey Dinneen: These are extraordinary people doing extraordinary work, and this is The Leading Difference. [00:00:50] Hello, and welcome back to another episode of The Leading Difference podcast. I'm your host Lindsey, and I am so excited to introduce you to my guest today, Annmarie Ison. Annmarie serves as the Vice President and Head of Service at Elekta. With over 25 years of experience as a software development professional, Annmarie specializes in product development and software architecture for information management systems and radiation therapy delivery devices, specializing in software, inter connectivity, machine functionality, and clinical workflow. She is highly effective and directing all aspects of the software development life cycle. And is passionate about new technology, customer relations, and products that have the potential to enhance the standard of care in oncology. [00:01:37] Welcome to the show, and thank you so much for being here. [00:01:41] Annmarie Ison: Oh, thanks for having me, Lindsey. I'm really excited to be here and chat with you and see where this goes. [00:01:49] Lindsey Dinneen: Absolutely. Well, I would love, if you wouldn't mind starting by telling us just a little bit about yourself and maybe your current role. [00:01:58] Annmarie Ison: So my current role is Head of Service for the software products at Elekta. And these products support radiation therapy and medical oncology and for clinics to deliver therapy, both chemo and radiation therapy, in a more efficient, safe, and effective manner. I actually for many years was in engineering and this role in service is fairly new to me. It's only been about a year that I've been in this role. I sometimes wonder how I got here, but I think it really comes from the fact that I love interacting with customers. [00:02:42] I started with the company as a startup, and there were only about 20, 25 people when I joined. And so you did a little bit of everything. And one of the things that got me really excited was working with our customers, talking to them, finding out what they need, why they need it, what they're doing. And also occasionally having those uncomfortable conversations on why things aren't working and how we can make 'em better and how we can fix stuff. And so I think over the years I've done different, as I said, different roles. [00:03:22] I did some product management and went back to engineering again, and then recently took on this challenge of service because, yeah, I just love interacting with the customer for good and for bad, and I really want to help them be better, help us be better by helping them be better and do their jobs in a easier way so that they can focus more time on the patients and less time on the stuff that they have to do. The computer systems are everywhere. We all have to use 'em, right? We have email and we have everything. And I don't want our software products to be burdensome to them. I want them to be easy and streamlined and make their life easier, and again, so that they can make the patient's lives easier. [00:04:19] Lindsey Dinneen: I love that. Oh, thank you so much for sharing a little bit about yeah, your story and how you ended up in this new role. This sounds like a wonderful blend because you have this, I can already tell, this heart for other people making a difference. And then you have that combined with your love of people and your enjoyment with working with them and that's not always easy. So I love the fact that you're able to combine some of those passions. And I'm curious, how did you start getting involved with the company at the beginning, when it was first a startup? How did that all come out? [00:04:58] Annmarie Ison: That was really just by happenstance. I'm gonna go back even further and say, as a child, as a kid, nine, 10 years old, I loved science. I was always into science. I had experiments. I had a chemistry set in my bedroom. But I always just assumed that I would be a doctor. And I, it wasn't, this is gonna sound really weird. It wasn't that I wanted to be a doctor. I just assumed that's what one did. If you were good in science, you became a doctor. That's, that was the only path, and I really never gave my career choice-- it wasn't a choice, actually. It was the only path. [00:05:40] I never really gave it much thought until I got to college and of course I was pre-med and I started meeting my new classmates and talking with them about what, why they wanted to be a doctor, why they were drawn to the practice of medicine. And I realized really quickly that I wasn't, that wasn't me. That isn't what I wanted to do. I didn't have that-- I didn't aspire to practice medicine. And so I kind of pivoted and I went away from that completely and I studied physics. And I focused on physics. And to me, I picked physics because to me it's foundational. And plus, physicists have the best toys. We get to play with all sorts of cool things. [00:06:26] But to me it was foundational and it really helps you understand a lot of other disciplines, and at the same time I was into mathematics and other staff and-- this was many years ago, for those younger folks listening-- computer science as a degree, as we know it today, didn't actually exist back then, or at least not at a lot of universities, and certainly not the small liberal arts college that I went to. And the, but the courses around computer science were taught outta both the physics and mathematics departments, and so I was really fortunate to have these great professors who were, I consider on the forefront, at least to me, they were on the forefront of figuring out how to use computers, and I'll really say PCs, as a tool to connect the physical world and the digital world, and use it to do the things that computers are really good at and let humans do what humans are good at. [00:07:35] And, you could focus on the physical situation and the data collection and data analysis was all done by the tools that we take advantage of or take for granted today. Excel and things like that didn't exist back then. It's a long time ago. So anyway, it, kind of pivoted away from that, from healthcare and being a doctor altogether and focused on physics, went to graduate school. And when I left graduate school, I really wanted to do exciting things like pay rent and eat. [00:08:09] So I found myself in aerospace and it was really interesting. I, I also found myself in Silicon Valley. I met my husband who grew up there, so that's where we wound up, and in aerospace I had, like I said, it was a cool job. I liked it. I was working on satellites. I, GPS was kind of a new thing then. It was really just coming into its own. And I even got to work bit on the space shuttle, so I, I was very excited. I was happy to stay in that role, but unfortunately the job moved out of the Bay Area and I had found myself going what do I wanna do with my life now? [00:08:58] But there were so many exciting things happening in Silicon Valley at the time that I I mean, it looked, it felt like there was a startup on every corner or really in every garage, right? And I just really, by happenstance, found this startup. And during my discussions with 'em, I met the principals and they shared their vision with me and it just resonated. They were working to change the face and the trajectory of radiation oncology, and when they explained their vision, I saw it, and I also saw a path to get to that vision. [00:09:48] Even more so, I felt like I saw how I could bring everything that I had done up to this point-- my physics background because there's a lot of physics in radiation oncology, my safety background for man's space flight, and my desire to do good and help people from when I was a little girl thinking about being a doctor-- I was able to bring all of that together into this one job. And I'm gonna say I was hooked and I haven't looked back. I've been doing, I've been with the company aiming for that vision really for the last 29 years. And I'm still striving for that vision because it really was a visionary that we're not quite there yet. There were paradigm shifts along the way, and we hit those and helped change how things are done and really form a market, but we're still striving. We're still striving to do better. [00:10:48] Lindsey Dinneen: Yeah. Yeah. Thank you. Thank you for sharing about that background. I love how, I just love when a pathway isn't, isn't as straight as we necessarily think it's gonna be. It's kind of funny how, you said looking back, it was almost like this expectation of, I'll be a doctor. And then you were able to, yeah, to take your interest in science, but your interest in lots of other things as well, and then form this career path that's probably looked unexpected, but seems to have wound you up in a place that you feel at home? [00:11:23] Annmarie Ison: Yeah totally. I do feel at home and sometimes I wanna go back to that nine, 10 year old self and go, "see, see, there isn't one path, there are options." There are so many different people and disciplines and viewpoints and technologies that are all needed to change healthcare, to advance the standard of care and the standard of practice. And you can make that difference by bringing your own set of skills, your own viewpoints, your own passion, and by just being you. And I hope that people hear that and realize that there isn't one path. [00:12:06] Lindsey Dinneen: Yes. . Thank you. I am completely in agreement with you, but I also just appreciate that, that you shared that particular advice because I think you're absolutely right. There are always multiple avenues to a dream and what might work for one person might be a different path for someone else. Well, so are there any moments that stand out in particular as just having this moment of realization that you are where you're supposed to be, like you're in this field, you're at this company, you're doing this particular work. Just any, anything that stands out in particular as, "Yes I am, I am in the right place at the right time." [00:12:51] Annmarie Ison: Oh goodness. I mean there, it's been a long career. So there are so many things that I'm proud of, but there's a moment that sticks in my head from many years ago. Maybe about two or three years after I joined the company, there was a new forum, a new technique in radiation therapy that was trying to become --I'm gonna just call it mainstream or standard clinical practice-- but there was a challenge there that the amount of data that was involved in preparing the patients for the treatment was huge. Hundreds, thousands of pieces of data that the medical physics team had to check and recheck and do measurements on. And it took a lot of effort and we were working with some of our customers to tried to streamline that process and provide them the confidence. Some of these checks, again, people can do those checks, but computers can do those checks really fast. And so we were working with a number of customers and there was one night, and like I said, it sticks in my head. I was in a, can I say I was in a bar in Saddlebrook, New Jersey of all places? [00:14:06] Lindsey Dinneen: Of course. [00:14:07] Annmarie Ison: You're up in New Jersey, so maybe that's why it sticks out. But where I was talking with a colleague, a customer, and we were gonna give a seminar the next day, and he had just, he was putting his slides together and going over them with me, and he had told us that he was able to get this effort that took him like 30 to 40 hours down to about an hour, and we were like, "Wow, that's awesome. That's fantastic." And we were really excited about that. But it was the thing that he said next that really stuck with me. And there's two points on it. The first is he said, "And now we don't have to choose. If the clinical indication requires this kind of treatment, we can offer it." [00:14:54] And that just hit me and I was like, "Wow, we moved the needle. Right? We really moved the needle." And I just, I was really excited about that statement, but it also hit me in a slightly different way. It reminded me that in all the rush to, in the day-to-day responsibilities of getting these features to the market, and who has to sign what paper, and what form has to be done, and what project plan has to be completed, and all those things that I actually didn't think about the patient. I'd forgotten about the patient. [00:15:35] And really since that day-- I actually felt bad about myself when he said it. I was frustrated and angry at myself for not thinking, not keeping that patient and that set of patients in mind-- that really since then, every day I think about the millions of patients that are impacted by the products that we work on. And I also think about each individual patient. When I'm never sure about, "Is this the right thing we should do? Are we working on the right thing? Is it good enough?" I think about the patient, the individual who could be anyone. It could be your brother, your sister, your spouse, your next door neighbor, child as well as I think about that vast set of patients that can be impacted. [00:16:24] And it helps recenter me and refocus me to make sure that I know I'm doing the right thing. And it's just stuck with me all those years. I'm a little bit of a broken record at work when I say, "Two and a half million patients, two and a half million patients," , or I say, "What about the patient? What about the patient?" But, I think in the end, it serves us well to do that, to always keep that in mind. [00:16:52] Lindsey Dinneen: Yes, absolutely. And, thank you so much for sharing that story. That's powerful. And so I know that women's health and advocacy for femtech, whatnot, that's something that you are interested in and passionate about. And I was wondering if you could share just a little bit about maybe your experience. [00:17:13] [00:17:14] Annmarie Ison: Yeah, so I think that access to care is really the key thing. And, whether it's women's health-- which I think is a huge issue of getting access to care-- but it can be anyone really. As I mentioned in the previous discussion about bringing these advanced techniques to the clinical setting, there are areas of the world that, that don't have the resources. And the resources could be basics like electricity and access to power and things like that. But also, the resources of skills. Right? [00:17:56] As I mentioned, medical physics is a big part of radiation therapy and if you don't have really skilled medical physicists around, it can be difficult to use these really advanced techniques that can, provide better care, fewer side effects, shorter treatment times. Again, when if you're looking at someone who has to travel a long way to get to care, you don't want them to have to come back every day for 25 or so days. If you can shorten that down into a week or so, which we can with some of these really advanced techniques. [00:18:35] But again, you need those resources, you need those expertise, and I think that's where I. The digital world comes into play again. And if anything, the pandemic taught us that we can do so much remotely. I can be, and we have this already today, can have medical physicists from some of the leading clinics in the world, here in the United States as well as in Europe, looking at and supporting countries that don't have that same baseline of resources and technical expertise. [00:19:10] And I think, women's health comes into play there a lot in that there are many indications in that are managed by radiation therapy. So I think, again, being able to offer these advanced techniques, shorter timelines, hopefully higher cure rates, or at least control rates, to these emerging markets, and expand access to care is really important to me. And I feel that's the direction that we have to go with in the, in healthcare in general. Access to care is the key. [00:19:47] Lindsey Dinneen: Yeah. Yeah. Thank you for speaking to that and elaborating a little bit on, on that, and I, I, I appreciate the fact that that you and your company in particular are aware of those issues and are thinking through them and talking about them and, that's how change is gonna happen. So, it's always exciting to see that. [00:20:08] Annmarie Ison: Yes. [00:20:09] Lindsey Dinneen: Yeah, absolutely. So, pivoting the conversation, just for fun. Imagine someone were to offer you a million dollars to teach a masterclass on anything you want. It could be within your industry, but it doesn't have to be. What would you choose to teach about and why? [00:20:30] Annmarie Ison: Oh my goodness. I think fundamentally I have a hard time with this question because I don't consider myself a master of anything. I always consider myself an intermediate, because as I learn, I realize how much more I don't understand about them. But for the million dollars, and I'll take it, I think it would have to be something around cooking. I love to cook, but I wouldn't want to talk about technique, mastering a specific chopping technique or sauteing technique or whatever. But I think I'd call it "collaborative cooking." I have so many friends who are intimidated by cooking and, "Oh, I don't know how to cook. I don't have a recipe." But I just can't think of anything more fun than to work as a team, bring everyone's different perspectives and skillsets and passions, if you wanna use that word, together, to bring a nice meal on the table and if things go wrong, well, that's part of the experience. [00:21:38] I also think that if you don't cook and you can still be a part of the team. My, my family does this, my family and friends, we do this all the time. Someone, we have three or four people in the kitchen, all cooking together. Someone made the menu, someone else has picked the wine, someone setting the table. Hopefully someone's pouring the wine too, but we all come together and it makes everything less, like I said, intimidating. You don't, you shouldn't be intimidated by cooking. It's fun and there's nothing better than enjoying a nice meal prepared by all of us together. [00:22:16] And that's my feeling about a team also is when you have a team working with food, like I said, dinner, it's no one's thing. It's everybody's thing. We all came together to make it so it's no longer, "I cooked this." It's, " We cooked this, we did this, and we made this wonderful evening or afternoon or whenever it is." You're enjoying it. So that would be my theme of the masterclass, if I could. [00:22:50] Lindsey Dinneen: I love that. Oh, I love that. [00:22:52] Annmarie Ison: Yeah, just, cooking with my nieces and nephews is always fun, and everyone coming together to enjoy and celebrate. [00:23:01] Lindsey Dinneen: Yes. . Yes, that is very exciting. And hopefully, like you said, the, the teamwork component of it will be joyful as all the families get together . [00:23:11] Annmarie Ison: It can also be, I call it, "passionate." It can be . It can also be passionate at times, like... [00:23:19] Lindsey Dinneen: I love it. [00:23:20] Annmarie Ison: ...someone can feel strongly about the temperature that cookie should be cooked at. I don't know. [00:23:25] Lindsey Dinneen: Yeah, that's right. And we're all working together towards a common goal, so gotta figure it out. . Amazing. Amazing. How do you wish to be remembered after you leave this world? [00:23:38] Annmarie Ison: This question, I'm gonna have a hard time with answering without getting very emotional. My husband passed away a few years ago, and he was in medical devices as well. We actually have a very similar background, he was a physicist, went into medical devices and we actually talked about this when we knew the end was nearing. And his answer was, "I want to be remembered that I helped." And I can't think of a better answer. I would love to be remembered that way, that I helped in some way, in all sorts of ways, that I helped my family and friends in times when they needed help, whatever that was, might be cooking something for them. But also that I helped forward this vision that the founders of the company had that I helped clinicians help their patients, and that I had some small impact on the standard of care and the direction of oncology. Yeah, that's the way I would like to be remembered, that there was some help. I can't think of anything better than that. [00:24:51] Lindsey Dinneen: Yeah. That's beautiful. That's a wonderful thing to aspire to. Thank you for sharing those stories, really appreciate it. And last but not least, what is one thing that makes you smile every time you see or think about it? [00:25:07] Annmarie Ison: Oh man. I feel like I should say something honorable like my family and friends and things like that, but they would all know that I was lying if I said that. They know the answer. The answer is pandas. [00:25:25] Lindsey Dinneen: Yes. [00:25:27] Annmarie Ison: I love pandas. As a little girl, I had a stuffed panda instead of a teddy bear, and I became a bit obsessed, and I consider myself now a recovering panda- holic. I had a rough week when the pandas left The National Zoo. It was very emotional for me, but I still lean towards pandas. I can't help but smile and laugh when I see them, and if you were to look under my desk on my early morning teams calls, chances are that I'm wearing my big fuzzy panda slippers while I'm taking those morning meetings. [00:26:09] Lindsey Dinneen: Oh. [00:26:09] Annmarie Ison: You dunno that, but I've got my big fuzzy panda slippers on most days. [00:26:15] Lindsey Dinneen: I love it! Thank you so much for sharing that. That just makes me smile. I love pandas, oh my word, and I just, every time I see those videos of those care takers trying wrangle the babies, oh my goodness. I love it. [00:26:34] Annmarie Ison: I, I, if I wasn't doing what I was doing and helping people this way, I, that's my dream job. [00:26:40] Lindsey Dinneen: Yeah. I have often said my retirement gig is gonna be a animal caretaking in some way. Oh my word. Well, this has been such a pleasure to speak with you today, Annmarie. I really appreciate you sharing a little bit about yourself and your background, how you came into this industry, and just your heart and passion for people, and making a difference. I really commend you and I just I thank you. Thank you for everything that you're doing to change lives for a better world. [00:27:10] Annmarie Ison: Oh, thank you. Thank you for having me. And I've actually listened to a number of your podcasts, so I feel honored to be a part of the group that you've talked to. And thanks. Thanks for inviting me here. I really enjoyed it. [00:27:24] Lindsey Dinneen: Thank you so much and thank you so much also to all of our listeners, and if you're feeling as inspired as I am right now, I would love it if you would share this episode with a colleague or two and we'll catch you next time. [00:27:39] Ben Trombold: The Leading Difference is brought to you by Velentium. Velentium is a full-service CDMO with 100% in-house capability to design, develop, and manufacture medical devices from class two wearables to class three active implantable medical devices. Velentium specializes in active implantables, leads, programmers, and accessories across a wide range of indications, such as neuromodulation, deep brain stimulation, cardiac management, and diabetes management. Velentium's core competencies include electrical, firmware, and mechanical design, mobile apps, embedded cybersecurity, human factors and usability, automated test systems, systems engineering, and contract manufacturing. Velentium works with clients worldwide, from startups seeking funding to established Fortune 100 companies. Visit velentium.com to explore your next step in medical device development. ​  

A conversation with Dr. Bodo Lippitz. Thank you to Elekta for sponsoring this episode! Find Elekta's services online at https://www.elekta.com/products/stereotactic-radiosurgery/elekta-esprit/patients-at-the-center/

No novo episódio do “CEO on Finance”, recebemos Deborah Telesio, CEO América do Sul da Elekta. Deborah nos contou sua inspiradora trajetória profissional, explicou seus desafios à frente da operação regional de uma companhia de tecnologia médica e compartilhou seus pontos de vista sobre temas como Diversidade e a postura que um CFO que almeja se tornar CEO deve ter.  Confira o episódio na íntegra aqui.

The field of oncology treatments is advancing very fast with innovative therapies and approaches on the market every day. It can get very tricky to support these therapies from an IT perspective, which is what you will hear more about in this discussion. I spoke with Anish Patankar, SVP and GM of Elekta's Oncology Software Solutions, and we discusses: How to go about the US hospital market,  Development in software for oncology treatments, Challenges in scaling healthcare IT software across markets.  Newsletter: https://fodh.substack.com/ www.facesofdigitalhealth.com Show notes: [00:00:00] Introduction to Elekta [00:02:00] Elekta's Global Presence [00:04:00] US Market Focus [00:06:00] Growth in Developing Countries [00:08:00] Segmentation and Technology Adoption in the US [00:10:00] Untapped Needs and Opportunities in the US [00:12:00] Elekta's Use of AI [00:14:00] Patient Feedback and Clinical Decision Making [00:18:00] Navigating Legacy Software in Healthcare IT [00:20:00] Modernization and Customer Satisfaction [00:22:00] Global Standardization and Regulation Challenges [00:24:00] Interoperability and Open Ecosystem [00:26:00] Future of Oncology Market Development: the interplay between medications and radiation, and the potential of theranostics. [00:28:00] Exciting Technologies in Healthcare Beyond Oncology: personalized healthcare, digital twins [00:30:00] Cautions for the Future: The critical debate on the balance between innovation speed and safety, particularly with generative AI.

Daniel Zetterberg, Daniel Svensson och Björn Rydell sammanfattar året och blickar in i 2024. Bolag som diskuteras i veckans avsnitt är bland annat: Spotify, Hoist, Volvo, Note, Evolution, Elekta, Green Landscaping och Norion Bank. Detta avsnitt av Affärsvärlden Analys sponsras av: Spotlight Stock Market https://spotlightstockmarket.com Letar du efter köpvärda aktier? Få inspiration och sök bland tusentals analyser i Affärsvärldens analysarkiv. https://www.affarsvarlden.se/verktyg/analysarkiv

In this episode, Anish Patankar, SVP & GM of Oncology Software at Elekta, discusses patient-experience data powering AI.

Welcome to the MassDevice Fast Five medtech news podcast, the show that keeps you up-to-date on the latest breakthroughs in medical technology. Here's what you need to know for today, October 24, 2023. Check out the show notes for links to the stories we discussed today at MassDevice.com/podcast. We are back for a new episode of the Fast Five after a week-long hiatus to focus on our DeviceTalks West conference in Santa Clara, California. Before we jump into the news you should know for today, we would be remiss if we didn't talk about the biggest stories from last week – J&J MedTech is restructuring its orthopedics business, and there's finally some insight into what caused the EU antitrust probe into Edwards Lifesciences' business. We break down the news we missed last week and more to get the show started. Plus, you can find all coverage from DeviceTalks West on MassDevice and on our sister site Medical Design & Outsourcing. This week, GE HealthCare announced a cardiac imaging collaboration with Boston Scientific. Fast Five hosts Danielle Kirsh and Sean Whooley discuss the goal of the collaboration and some of the highlights GE HealthCare is expected to showcase at TCT this week in San Francisco. iCad has sold its Xoft brachytherapy business to Elekta. Find out the value of the deal and what technology Elekta is acquiring in this deal, plus executive reactions.  The FDA cleared Insulet's iPhone app for Omnipod 5. The clearance is a long time coming. Hear what makes this clearance significant, what analysts think and some of the challenges that had to be overcome to make the Omnipod 5, according to Chief Technology Officer Mark Field during a DeviceTalks West conversation. Philips posted Q3 earnings results this week that included an increased outlook for the year despite ongoing role reductions and the implications of the Respironics recall. Whooley details the financial highlights of the quarter, what the company attributed the growth to and the updates Philips provided regarding the Respironics recall. Medtronic won an FDA nod for its extravascular defibrillator. Find out what the system is and how it works, and what doctors think about the technology in today's episode.

Libri: M. AIkins, Chi è nudo non teme l'acqua, trad. L. Fusaro, Iperborea; Poesie delle Americhe, a cura di P. Gelli, Elekta. Musica: Sufjan Stevens, Afghan National Orchestra, Green Day, Alberto Rey y su Consunto, Violetta Paura, Arcade Fire.

To shed some lights on the future of oncology, today we are joined by two acclaimed guests, Chaitanya Sarawate, President & CEO of GE HealthCare South Asia and MD, Wipro GE Healthcare; Manikandan Bala, SVP, TIMEA & APAC and MD, India & South Africa at Elekta. In this episode of GE HealthCare's podcast series, we will explore the cutting-edge technologies and breakthroughs that are revolutionizing cancer treatment, while also delving into the hurdles and complexities associated with it. Make sure you tune in to get a deeper understanding of the vital role played by Artificial Intelligence (AI) and Precision Care in advancing cancer care.

Join us LIVE Sunday @ 7:30pm CST as we discuss the following! 0:00 - Intro/Honorable Mentions (Blue Beetle, Smallville, SuicideSquadISEKAI) 20:29 - Deadpool 3 Cameos Galore! Jennifer Garner as Elekta, Channing Tatum as Gambit? + More! 43:40 - Has the Fantastic Four Found Their Sue Storm in Vanessa Kirby? 55:22 - Disappointing Shang-Chi 2 Update as DELAY is Likely! 1:06:21 - The CURRENT State of Movies and The Box Office! What's Happening? 1:36:48 - Zack Snyder's BIG Plans for "Rebel Moon" Expansion! 1:45:45 - Two New Chronicles of Narnia Movies Coming from Netflix & Greta Gerwig 1:55:59 - LIVE VIEWER QUESTIONS Join Our Discord Forum Community: https://discord.gg/uKstHsY A+ Amazon Wish List: https://www.amazon.com/hz/wishlist/ls/22BG60615YS0M?ref_=wl_share Contact/Email: aplusopinions@gmail.com Facebook: www.facebook.com/aplusopinions Twitch: Twitch.tv/aplusopinions Twitter: @aplusopinions IG: @aplusopinions IG: @animeassembled #Deadpool3 #VanessaKirbyFantasticFour #ShangChi2 --- Support this podcast: https://podcasters.spotify.com/pod/show/aplusopinions/support

Elekta Limited v. ZAP Surgical Systems, Inc.

Millionærklubben tager hul på sidste børsdag i ugen og klubbens to forvaltere, Lau Svenssen og Lars Persson, svarer på spørgsmål fra lytterne. Med på telefonen er også Jens Bjerg Sørensen, CEO i Schouw & Co., med en kommentar til dagens aktuelle regnskabstal og selskabets syn på fremtiden. Vært: Bodil Johanne Gantzel.  I dagens afsnit kan du høre om følgende aktier: NKT, Subsea 7, Rockwool, Novozymes, Elekta, Arjo, Nokia, Tesla, Norden, Genmab, Shell, Evolution Gaming, H+H  og Nobia.See omnystudio.com/listener for privacy information.

I veckans avsnitt tipsar Di:s Ulf Petersson och Torbjörn Isacson om två intressanta aktier samt diskuterar vad den stora förändring som pågår i industriföretaget Trelleborg kan betyda för bolagets framtid. Även veckans innehållsrika bokslut från Ilija Batljans fastighetsbolag SBB avhandlas. Som veckans case lyfter Ulf Petersson fram medicinteknikbolaget Elekta som efter ett par år med försämrad rörelsemarginal kom med en riktigt stark rapport under fredagsmorgonen.

Wat is er intelligenter dan Artificiële Intelligentie.. Evolutionaire Intelligentie!Bij traditionele berekeningen van neurale netwerken (denk aan gradient descent of aanverwante berekeningsmethoden) wordt de oplossing voor een gegeven probleem berekend uit een enorme hoeveelheid mogelijkheden waarvan een groot deel ook technisch of fysiek onmogelijk is. Bij Evolutionaire Intelligentie werkt dit anders.Peter Bosman van het Centrum voor Wiskunde en Informatica heeft een methode ontwikkeld waarin een vorm van evolutionaire algoritmen die "intelligent zoekgedrag" vertonen en die kunnen leren hoe een probleem in elkaar zit om betere oplossingen te vinden. Door het algoritme te laten gebruik maken van kennis over hoe stralingsdoses opbouwen vanuit katheters, heeft het team veel betere resultaten behaald dan met andere algoritmen.  Niet alleen is de oplossing transparanter omdat er geen black box algoritme gebruikt wordt, maar ook is het mogelijk om de oplossing beter als in genuanceerder (multi-objective) af te stemmen op wenselijke optima voor diverse gebruikers. Deze algoritmen zijn bijzonder effectief en efficiënt in het vinden van goede oplossingen voor complexe problemen, vooral wanneer er meerdere tegenstrijdige doelen zijn.  Bovendien is de methode computationeel sneller dan traditioneel methoden, dus meer doen met minder rekenkracht. Use case - optimale bestraling bij prostaatkanker (brachytherapie)Het team van onderzoekers van het Centrum Wiskunde & Informatica (CWI) in Amsterdam, onder leiding van Peter Bosman, heeft een zelflerende software ontwikkeld die het mogelijk maakt om binnen 30 seconden een reeks geoptimaliseerde behandelplannen voor prostaatkanker te berekenen, waarbij gebruik wordt gemaakt van evolutionaire algoritmen. De artsen die de software gebruikten om de bestralingsplannen te maken waren verrast door de snelheid en kwaliteit van de plannen die de computer voorstelde. Het gebruik van deze technologie kan de radiotherapeuten helpen om meer geïnformeerde beslissingen te nemen over de beste manier om patiënten te behandelen en de behandeling te optimaliseren.Bij Bosmans onderzoek verliep de samenwerking tussen artsen, onderzoekers Elekta uitstekend. Maar dat is bepaald niet vanzelfsprekend, aldus Bosman. ‘Het vereist een hele hoop afstemming. Als team werken we verspreid over het CWI, het AMC en de Elekta-vestiging in Veenendaal. Om de neuzen in dezelfde richting te houden en elkaars vaktaal te leren spreken, zitten alle onderzoekers twee keer per week bij elkaar, afwisselend op het CWI en op het AMC. Daarnaast gaan de onderzoekers elke vier weken naar Elekta en hebben we elke zes weken een update meeting waar iedereen aanschuift, ook artsen en klinisch fysici. Zo kunnen we samen naar resultaten kijken en van elkaar leren wat nu belangrijk is. We zijn zo echt tot een team uitgegroeid.'De Dataloog is de onafhankelijke Nederlandstalige podcast over data & kunstmatige intelligentie. Hier hoor je alles wat je moet weten over de zin en onzin van data, de nieuwste ontwikkelingen en echte verhalen uit de praktijk. Onze hosts houden het altijd begrijpelijk, maar schuwen de diepgang niet. Vind je De Dataloog leuk? Abonneer je op de podcast en laat een review achter.

“This is an innovation… something people thought was impossible. It really changes the game in how we deliver radiotherapy to cancer patients.”Fighting cancer is not an easy task. Each body responds differently and each tumor is unique - so treatment must be personalized and precise. But, as companies like Elekta push forward advancements in the field, cancer care is becoming more targeted and effective than ever before.Elekta is a company creating cutting-edge linear accelerators, devices that deliver life-saving radiation therapy. In this episode we meet Chris Gilpin, Chris Flint and Mark Range at the company's HQ in the UK. Find out how radiation therapy works, and why it's playing an increasingly important role in cancer prevention. Get up close with the machines and take a tour through the factory to see how they're built. And learn how Elekta's IntelliMax system is bringing radiotherapy to underserved and remote countries all over the world.We also hear from Howard Heppelmann who heads up PTC's Industrial Internet of Things division. He explains how ThingWorx enables Elekta to respond rapidly to issues, and communicate quickly with their customers, so treatments go uninterrupted. Find out more about Elekta here.Find out more about ThingWorx here.Your host is Paul Haimes from industrial software company PTC. Episodes are released bi-weekly. Follow us on LinkedIn and Twitter for updates.This is an 18Sixty production for PTC. Executive producer is Jacqui Cook. Sound design and editing by Ollie Guillou. Location recording by George Powell. Music by Rowan Bishop.

SD153 Elekta: Líder mundial em radio-oncologia. Neste episódio, a conversa é com Deborah Telésio , VP da Elekta para a América do Sul. Ela nos conta sobre a multinacional sueca especializada em tecnologia médica de radiologia de precisão. A Elekta tem seus equipamentos para radioterapia, radiocirurgia e braquiterapia apresenta em mais de 6.00 hospitais no mundo e investe nas inovações no tratamento do câncer com suas soluções, utilizando a inteligência artificial. Neste episódio, o que você vai encontrar: O background da Deborah  Experiência de 20 anos no mercado de saúde na área de equipamentos médicos. Formada em Marketing, ela trabalhou na área de consumo e entretenimento. A área de saúde através da GE, trabalhada por 14 anos, permanecendo em Markenting, mas depois migrando para a área de negócio de equipamentos. Mudou para a Elekta e sente que tem um propósito ao trabalhar com uma área de atuação em tratamento. Um pouco da Elekta Empresa sueca com 50 anos de atuação no mercado, nasceu do desenvolvimento de uma tecnologia em radiocirurgia intracraniana não invasiva; Inicialmente foco em Neurologia com uso de Radiação de Precisão e não há paralelo ao Gamma Knife no mercado; A aquisição de empresas e desenvolvimento de tecnologias na medicina e na braquiterapia; Tecnologia topo: Equipamento Unity unindo magnéticos e acelerador linear. Benefícios da Unidade Possibilidade de ver mais e ver melhor a adaptação do tumor: detecção dos movimentos e possibilidade de leitura rápida para garantir que o certo está sendo atingido no lugar e que os tecidos estão sendo preservados. Um diferencial tecnológico do Unity Precisa que traz o serviço de tecnologia para o ponto certo e dose certa; Tecnologia desenvolvida para acompanhar o movimento da lesão e irradiar de acordo com esse movimento e a paralisação imediata da irradiação, se houver fuga do ponto certo. Onde estão as soluções Gamma Knife: 4 equipamentos no Brasil, sendo 1 no HCor em SP; Unity: ainda não disponível no Brasil. O retrato da radioterapia no Brasil Apenas 360 equipamentos de radioterapia no país, sendo que, em 50% dos equipamentos, estão obsoletos. A Elekta tem 120 equipamentos no país. Para o paciente, o uso do Versa HD Beneficiando-se na Eleta Eleta paciente, o paciente é tecnologia da menos sessões de precisão e maior com maior dose por sessão e precisão. Isso se traduz em rapidez no tratamento, segurança e mais pacientes sendo atendidos. Conheça um pouco mais sobre a Débora Telésio e como ela sobreviveu ao Tsunami em 2004: OUÇA !  Podcast da Comunidade Online Saúde Você é médico? Quer interagir com Lorenzo Tomé e com outros pesquisadores inovadores da medicina digital?  Entre na Comunidade do Podcast Saúde Digital na SD Conecta! Assista este episódio também em vídeo no YouTube no nosso canal Saúde Digital Ecossistema! ACESSE AQUI ! Episódios Anteriores - Acesse! SD152 - MV Sistemas: Solução de Integração de Prontuários para médicos SD151 - GRUPO DEDALUS: líder mundial em software de saúde SD150 - ISA LAB: A Descentralização do Home Care SD149 - A Carreira do Médico Militar SD148 – Cardiopapers - A escola digital de 35 milhões de reais . Música | Declan DP -  Island " Música © Copyright Declan DP 2018 - Presente. https://license .declandp.info | ID da licença: DDP1590665"

I det sista avsnittet för säsongen analyserar Daniel Zetterberg och Björn Rydell bolag som Bonesupport, Elekta och Emilshus. Det blir även en del obligationsprat, och som vanligt en genomgång av IPO-guiden. Dessutom pratar vi SBB, tar en titt på AFV-portföljen och diskuterar vad som hände med vår post i Academedia. Detta avsnitt av Affärsvärlden Analys sponsras av: Spotlight Stock Market https://spotlightstockmarket.com

In this week's episode, I am interviewing Anna Blixt, who is working with Global Employer Branding at Elekta in Stockholm. In this episode, we will learn about how she transitioned into an Employer Branding role from previously working in Sales, as well as her experience in joining a Mentorship program by the Swedish-American Chamber of commerce in New York. With years of experience in both Employer Branding and Sales, you'll get to know what her best career tips are along with her biggest career challenge so far. 

Best Medical International, Inc. v. Elekta Inc.

Best Medical International, Inc. v. Elekta Inc.

Best Medical International, Inc. v. Elekta Inc.

Best Medical International, Inc. v. Elekta Inc.

Recbecca joins us for a special release to discuss the variations in Medical Physics between Australia, Canada and the United States!

Seasoned Healthcare Executive with proven skills for people development, organizational transformation, and motivation with 15 years delivering above and beyond financial results. Mr. Pastor has an exemplary external focus and is highly collaborative with customers and a wide range of stakeholders to match the company with customers' needs. He is very adaptive and able to connect strategy to purpose in a way that fosters commitment, Javier has the imagination to innovate and the courage to implement organizational changes and go to market strategies highly inclusive and able to build great teams.

Rebecca joins us for a special release to discuss the variations in Medical Physics between Australia, Canada and the United States!

Rebecca Moylan comes on the show to share her experiences in clinical medical physics, and how those expereinces shaped her adventures into the corporate side of RadOnc with Elekta as a Physics Specialist!

Placera-TV: Handelsbankens förvaltare Christian Brunlid kommenterar flera av dagens kvartalsrapporter. Bland annat om rapporterna från Cellink, Elekta, EG7 och Sedana. Dessutom om utsikterna för småbolag och om första handelsdagen för Desenio. Aktier: Cellink, Desenio, EG7, Elekta, Implantica och Sedana Samtalet spelades in den 25 februari 2021 Se samtalet och graferna: https://www.avanza.se/placera/redaktionellt/2021/02/25/medtechvarldens-svar-pa-embracer.plc.html (Beklagar sämre ljudkvalitet)

Placera-TV: Placeras trio Pär Ståhl, Jesper Norberg och Karl Lans diskuterar rekord för börsnoteringar, överoptimism, Siemens avknopnningar och lärdomar från Sectra. Dessutom pratar vi om några av våra egna affärer den senaste tiden. Aktier: Airbnb, Bayer, Elanco Animal Health, Elekta, Fasadgruppen, Infineon, Palantir, Sectra, Siemens, Siemens Energy, Siemens Healthineers, Splunk, Swedbank och Thunderful Se samtalet: https://www.avanza.se/placera/redaktionellt/2020/12/11/darfor-har-vi-rekordmanga-kursdubblare.plc.html (Beklagar sämre ljudkvalitet)

W tym odcinku gości u mnie Krzysztof Głośnicki - współautor Zony i autor Elekta, założyciel wydawnictwa gier planszowych What The Frog, gdzie spełnia się jako projektant i game developer. Stawia na gry z mocno zarysowanym tematem. Od wielu lat trener warsztatów planszówkowych dla dzieci i dorosłych. Uwielbia uczestniczyć również w grach fabularnych - jest autorem poradnika "Mistrzowanie RPG".

Laurent “Larry” Leksell is the co-founder of Elekta, a global company that is pushing the boundaries of radiation therapy to provide access for advanced, high-quality cancer care. While studying at the Stockholm School of Economics, Larry jumped into entrepreneurship with his father who had a passion in cancer research. Larry now sits as a chairman and principal shareholder of Elekta while he fulfills his passions of philanthropy, entrepreneurship and art.In this podcast:Founding Elekta with his fatherHis life dedication to solutions for cancer His passions for philanthropy, entrepreneurship and artCancer care innovation and resourcesEntrepreneurship expectationsLong-term business solutions See acast.com/privacy for privacy and opt-out information.

• Positive risk sentiment following Germany extending extends wage support program to end of 2021 which saw steepening of yields with 10Y Bunds selling off by over 7bp. Risk on rotation evident in equity mkt too as Telecoms, Utils worst performing. • Also some positivity on the US/China del front as China was reported to be set to buy a record amount of American soybeans after reaffirming its commitment to the phase-one deal with the US earlier this week. ove to restore friendly Europe Ties • Tech outperforming +1% • Telecoms underperforming Hoever.. Telecom Italia +4% on decent volume post press spec. that Italy Unlikely to Block Telecom Italia Deal With KKR re: Networks sales. • Energy only small up is underperforming despite crude maintaining the $45 price after more headlines around Hurricane Laura hitting production. • PROVIDENT FINANCIAL +16% there were some +ve comments on Con call..competitive landscape --- COVID will expand their addressable market place; CEO talking up balance sheet strength • Ambu -14% in Copenhagen after the resuscitator-maker lowered its full-year growth and profit forecasts. • Elekta +15% loads of incoming all from clients who think this rally is too much, that said 1Q order intake was more resilient than expected, EBITA beat cons by +19% on favourable sales mix and solid cost control however market seems to be blind to the fact that the co expects 2Q to still be impacted by COVID and is not issuing FY guidance. • Aroundtown S.A. rose as much as 3.9% in Frankfurt after reporting a jump in half-year revenue. • FERRAGAMO(SFER IM) +6% post Jefferies u/g to BUY this am p/t 15 fm 11 • Macro French PM Castex commented on radio France to unveil economic stimulus plan on 3-Sep: further hints about the contents of its €100B plan to boost the economy with full details of the stimulus package to be announced on 3-Sep

Zoom: Handelsbankens småbolagsförvaltare Christian Brunlid kommenterar dagens kvartalsrapporter från Elekta, Scandi Standard, I-Tech och Smart Eye. Dessutom om budet på HiQ, tankar inför börshösten och om en sektor som kan ha tagit för mycket stryk. (Beklagar sämre ljudkvalitet) Se samtalet: https://www.avanza.se/placera/redaktionellt/2020/08/26/brunlid-jag-raknar-med-en-bra-borshost.plc.html

Chaired by David McGoldrick, Chief People Officer for Comfort Keepers, the discussion brought together perspectives from Asif Iqbal, Vice President of HR for Gulf Oil, Melanie Lepine, Group Head of Learning, Development & Talent from Domestic & General, Ben Almond, SVP and Global Head of Property from Pearson, Simi Dubb, Group Head of Talent, Development and Inclusion at British American Tobacco and Tim Rose, Global Head of Facilities for Elekta, to share their insights on "How to create a productive working culture for a varying workforce in the current climate."

Get ready for a very inspiring story. We’re glad to have with us today, Josh Perry, a Pro BMX Athlete and a Multiple Brain Tumor Survivor.   Josh Perry was born and raised on Cape Cod, MA, where he developed his passion for BMX bike riding. When he was 17, he moved to Greenville, NC to ride with the best riders in the world, including Dave Mirra, and pursue a career as a pro BMX athlete. In April of 2010, at the young age of 21, Josh underwent surgery to remove a brain tumor, taking up the entire left side of his brain and leading him to go blind. In November of 2012, he had Elekta’s Gamma Knife Radiation treatment to treat two areas of re-growth from the initial surgery.   With his experiences with brain tumors and injuries, Josh became very passionate about learning about food and the correlation to our health and wellbeing, as well as sharing information with others in hopes of helping them become well.   Today, Josh and I talked about his journey to becoming a BMX Athlete, and his experience in learning he has a brain tumor. What a strong and inspiring man he is! We also talked about food and nutrition, and his passion for helping others become well.   Episode Highlights:   ●       Resilient Josh Perry: Pro BMX Athlete & Brain Tumor Survivor  [3:38] ●       Josh’s Post-Surgery Recovery [13:32] ●       Gamma Knife Radiosurgery: Josh's Second Round of Treatment  [15:38] ●       Becoming Health Conscious [18:10] ●       How to Test and Track Your Blood? [22:05] ●       Simple Health Tips and Advice for Everyone [27:27] ●       A Peek Through Josh’s Typical Day [30:15] ●       Electrolytes and Exogenous Ketones [35:00] ●       Book Recommendations [38:58]   AND MUCH MORE!   Resources Mentioned In This Episode: ●       If you are a future or aspiring business leader who wants to achieve the next level of success in your profession, get started by getting my FREE video short course: The Secret to Unleashing Your Top 1 Percent. ●       Get to know more about Josh Perry, his inspiring story of being a brain tumor survivor, and his eating habits through his website: joshperrybmx.com. ●       Connect with Josh: o   Facebook o   Twitter o   YouTube o   LinkedIn o   Instagram o   Email   ●       Book Recommendations: o   Grain Brain by David Perlmutter o   The Ketogenic Bible by Jacob Wilson o   Think and Grow Rich by Napoleon Hill o   Breaking the Habit of Being Yourself by Joe Dispenza   Quotes:   “About 70-75% of our genes can be influenced with lifestyle.” “What we think, act, and what we consume affect our genetic makeup.” “When you get hit in the head, your glucose uptake in the brain for energy goes down. But, the transporters that shuffle ketones from the blood into the cells go up.” “It’s not diet. It’s a lifestyle.” “Part of the process is learning how to critique meals and snacks on the go so that way, you can live this lifestyle.” “When you are on a low carbohydrate ketogenic diet, you are reducing the amount of starch and carbohydrates in what you are eating. When that happens, your blood sugar levels start to lower to an optimal range. In doing so, your insulin levels start to level as well.” “Salt is your friend. If you don’t have enough, you can be insulin-resistant to some degree.”   Ways to Subscribe to The Top One Percent:   Apple Podcast Stitcher PlayerFM Podtail

Host David Harlow sits down with Richard Hausmann, PhD, CEO of Stockholm-based linear accelerator manufacturer Elekta. MRI guidance and AI are improving radiation therapy targeting accuracy, reducing doses and making radiation therapy available in a broader range of cases, thus improving patient outcomes. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask Siri or Alexa to “….Play HealthcareNOW Radio”. Find all of our show episodes on your favorite podcast platforms. www.healthcarenowradio.com/listen/

I sista avsnittet för decenniet summerar Erik och Jonas 2019 och blickar framåt. Börsens utsikter diskuteras och intressanta teman. Erik redogör för vilka indikatorer han studerar för att få vägledning för börsen på 1-3 månader. Jonas drar konklusioner från fondförvaltarenkäten. Som alltid bjuds det på bolagsobservationer.  00:00 Inledning av Börssnack.  04:00 Viktigaste händelserna senaste veckan.  08:00 Erik förklarar indikatorer han brukar studera.  13:20 Jonas konklusioner från fondförvaltarenkäten.  22:10 Riksbanken lämnar minusräntan. 27:50 Bolagsobservationer Peab, JM, Bulten, Nobia, Elekta 37:00. Teman inför 2020 (banker, EM). 38:40 Negativ realränta, guld i mer gynnsam period, stigande inflationsförväntningar. 43:10 Vi tackar alla som gästat Börssnack 2019. Följ Erik Hansén på Instagram: https://www.instagram.com/higherlows/

I detta avsnitt går Peter Benson, Daniel Zetterberg och Björn Rydell tveksamma kassaflöden och redovisningsmässiga förfaranden som går att ifrågasätta. Bolag som diskuteras i avsnittet: Elekta, Embracer, G5, Raysearch, Elos Medtech, XXL, Nokia och börsnoteringsaktuella Moba Network.

Länsförsäkringars småbolagsförvaltare Fredrik Skoglund gör sin debut i Placerapodden. Ett lång samtal om Fredriks bakgrund och hur han tänker kring investeringar. Fredrik ger sin syn på marknaden och går igenom flera av sina innehav. Samtalet spelades in onsdag den 13 november. Under samtalet pratar vi om flera aktier och sektorer. Ungefärliga tidskoder nedan: 01:55 Vem är Fredrik Skoglund? Fredrik berättat om sitt intresse för aktier och om hans bakgrund som analytiker och som förvaltare och hur han hamnade på Länsförsäkringar. Fredrik berättar också om hur han jobbar som förvaltare. 11:16 Fredrik berättar om fonden Länsförsäkringar Småbolag Sverige Fredrik redogör för fondens mandat. Bland annat om antal aktier fonden normalt har, placeringshorisont, storleken på aktierna och omsättningshastigheten. 15:32 Investeringsprocessen Fredrik berättar hur han tänker kring investeringar och hans fokus på vinsttillväxt. Fredrik berättar också om hur han hanterar motgångar och nämner aktier som inte har utvecklats som han hade tänkt sig. Aktier som nämns: Boozt och Proact 23:55 Höjdpunkter under Q3 Vi pratar om några av bolagen som har rapporterat och ett bolag som ännu inte har rapporterat. Fredrik ger även sin syn på aktierna för respektive bolag. Aktier som nämns: Elekta, Scandi Standard, Sinch och Troax 41:00 Tankar kring börsen Hur tänker Fredrik kring resten av året och var fokus ligger inför 2020. Fredrik berättar om sin syn på konjunkturen och rådande börsoptimism. 47:42 Några av Fredriks viktiga innehav Fredrik redogör för några av fondens större innehav och hur han ser på aktierna. Vi pratar bland annat om lagersituationen i Husqvarna, ifrågasatta kassaflöden för Embracer och Academedias låga värdering. Dessutom nämner Fredrik sektorer som han har låg eller ingen exponering mot. Aktier som nämns: Academedia, Embracer, Husqvarna, Paradox; Resurs och Stillfront

Healthcare Direkt är programmet där vi pratar om veckans händelser inom life science. I veckans avsnitt gästas vi av Scandidos vd Görgen Nilsson som berättar om bolagets rapport för det första kvartalet 2019/2020. Vi går igenom trender på strålterapimarknaden och behandlar den årliga ASTRO-kongressen, som är den största globala mässan inom området. ASTRO hölls i år mellan den 15-18 september i Chicago, USA. Elektas kommunikationsdirektör Oskar Bosson delar med sig av sina intryck från ASTRO-mässan. Han tar även upp de områden som Elekta valt att fokusera på under mässan. I nyhetsdelen belyser vi danska Lundbecks förvärv Alder Biopharmaceuticals inom migränmarknaden för nästan 2 miljarder dollar. Cellavisions förvärv av franska RAL Diagnostics omnämns samt Sanionas resultat från en fas 2a-studie med läkemedelskandidaten Tesomet i den sällsynta sjukdomen Prader Willis-syndrom.

Oncopeptides presenterade under den gångna veckan en riktad emission på 727 miljoner kronor. Callidatas och Surgical Science presenterade emissioner på i storleksordningen runt 200 miljoner kronor. Raysearch har sedan mitten av maj i år presenterat order till ett värde motsvarande nästan 160 miljoner kronor. Det är grovt sett samma nivå som orderingången låg på under andra kvartalet 2018. Storordern från Medaustron till ett värde om 12 miljoner euro står för den största delen av dessa order. Aktier/bolag som nämns i programmet: Callidatas Therapeutics, Elekta, Oncopeptides, Raysearch och Surgical Science. Ser du hellre programmet i videoformat? Välkommen att besöka vår kanal på youtube.com/playdirekt

Healthcare Direkt är programmet där vi pratar om veckans händelser inom life science. I veckans avsnitt, där vi går igenom finansiering av life science bolag, gästas vi av Annika Espander vd för Asperia. Annika Espander har varit med som rådgivare i flera framgångsrika finansieringar. Hon har 25 års erfarenhet som rådgivare och investerare i ledande befattningar inom finansmarknad på bland annat Handelsbanken, Enskilda Securities och Catella samt som styrelseledamot för medicinteknikbolaget Elekta och industrikonglomeratet Lifco. I nyhetsuppdateringen tar vi upp två storförvärv inom sektorn. Dels amerikanska Abbvies förvärv av Allergan för cirka 63 miljarder dollar. Allergan är kanske mest kända för Botox, men har också verksamhet inom ögonsjukdomar, central nervsystemet, mage/tarm samt kvinnohälsa. Vi pratar också om Pfizers köp av Array Biopharma för 11,4 miljarder dollar. Array Biopharma ligger bland annat bakom Astra Zenecas läkemedelskandidat Selumetinib. I linje med veckans tema om finansiering diskuterar vi A1M Pharmas riktade emission om drygt 27 miljoner. Ser du hellre programmet i videoformat? Välkommen att besöka vår kanal på youtube.com/playdirekt

St. Charles has deep routes in German, French and Spanish heritage, and with the addition of medical technology company Elekta, we are adding Sweden to that list. In this week’s episode of #MondayMinute learn about one of St. Charles’ newest employers coming to the Streets of St. Charles. Learn more about Elekta: https://www.elekta.com/ Listen on Soundcloud: http://bit.ly/RIB2018 Subscribe on Apple Podcasts: http://bit.ly/STCHMO Follow Us: Grow St. Charles Facebook: http://bit.ly/2Hnv47F Grow St. Charles Twitter: http://bit.ly/2C4mWKb The City of St. Charles Facebook: http://bit.ly/2obOxQd The City of St. Charles Twitter: http://bit.ly/1ERNLN7 For more information visit: http://growstcharles.com

Radiation therapy has been an approved method of treatment for cancer for many years. But there are still many mysteries about how it works, is it safe and more. Our guest today, Dr. John Christodouleas, is a researcher for Elekta, Inc., in the field of radiation and will explain how radiation therapy works and debunk the myths often associated with this method of treatment.This show is broadcast live on Friday's at 1PM ET on W4CS – The Cancer Support Network (www.w4cs.com) and W4HC - Health Cafe Live Network (www.w4hc.com) part of Talk 4 Radio (http://www.talk4radio.com/) on the Talk 4 Media Network (http://www.talk4media.com/)

Äntligen fredag och dags för ett nytt avsnitt där vi i vanlig ordning går igenom börsen och allt som rör de finansiella marknaderna! Det har varit en skakig börs efter G20 mötet, något vi självklart går in på! Sedan har vi finbesök i studion av intervjugurun Alexander Pärleros som bland annat ligger bakom Framgångspodden! Han ställer sina bästa frågor gällande vad man bör tänka på när det kommer till marknaden just nu, vilka branscher som är heta, vanligaste misstagen och hur man ska tänka kring sitt sparande! Vi går även in på några aktiecase, denna vecka oljebolag och Elekta! Tack för att ni lyssnar!  Erik Hansén twitter: twitter.com/erikhansen_ig  Jonas Olavi twitter: twitter.com/j_olavi?lang=sv

Då var det dags för ett nytt spännande avsnitt av Börssnack! Den här veckan går vi djupare in på ett område som är klurigt för många, nämligen räntemarknaden! Med oss i studion har vi Mikael Yman, ränteförvaltare på Alfred Berg som hjälper oss att förstå detta närmare! Vi gå dessutom som alltid in och diskuterar börsläget, hur ser vi på det stundande G20 mötet och de kommande PPM flödena? Slutligen tittar vi närmare på Oriflame och Elekta! Tusen tack för att ni lyssnar! Erik Hansén twitter: twitter.com/erikhansen_ig  Jonas Olavi twitter: twitter.com/j_olavi?lang=sv

Äntligen fredag och ett nytt avsnitt av Börssnack! Den här veckan ger vi er i vanlig ordning en update om läget på börsen där vi lägger extra stort fokus på H&M! Vi diskuterar även fastighetsaktier där vi har en spännande intervju med Jonas Andersson, förvaltare av Alfred Bergs Fastighetsfond Norden! Slutligen går vi in på lite intressanta bolagsspaningar, denna vecka Dustin och Elekta! Tack för att du lyssnar!  Erik Hansén twitter: twitter.com/erikhansen_ig   Jonas Olavi twitter: twitter.com/j_olavi?lang=sv

När krisen var som värst var Larry Leksell, grundare och nu styrelseordförande i medicinteknikbolaget Elekta, nära att ge upp. "Jag ville att styrelsen skulle byta vd, men de sa nej, så jag fick fortsätta", avslöjar han i lördagens avsnitt av Förnuft & Känsla. See acast.com/privacy for privacy and opt-out information.

Superentreprenören Laurent Leksell, huvudägare i Elekta, grundare av Leksell social ventures och tidigare ordförande i Stadsmissionen gästar veckans podd! Missa inte ett engagerande avsnitt där han ger sin bild av sitt liv som entreprenör så långt och historierna bakom hans företag och företaganden. Men också hans samhällsengagemang - och svaret på frågan hur man lyckas med sitt företagande! Dessutom - vilken är det sjukaste regelkrånglet för företagare som du råkat ut för eller hört om? Vi vill ha din story! (Günther delar med sig av en vi fått in...)

I veckans avsnitt av Fill or Kill får vi storfrämmande av ingen annan än självaste Larry Leksell ordförande i Elekta. Han berättar om sin uppväxt, gammakniven och hur det gick till när Elekta bildades.

Miljardären som grundat Elekta som har ett börsvärde på ca 30 miljarder! Självklart hör du lyssnarfrågor LIVE, tre bolagspitchar, mycket skratt och väldigt mycket bra insikter.   Rösta på Veckans Business i vår app så har du möjligheten att få en inbjudan till Businesspodden Awards.   Ladda ner appen i App Store: https://itunes.apple.com/se/app/businesspodden/id1318269951?mt=8

I veckans avsnitt pratar vi om det ständigt omdiskuterade ämnet Blankning. Först reder vi ut själva konceptet. När började det, hur gör man och varför förekommer blankning? Vidare diskuterar vi blankandets vara eller icke vara. Och vilka eventuella fördelar eller nackdelar på finansmarknaden som blir konsekvensen av blankning. Vi frågar oss även varför bolag som Intrum Justicia, Fingerprint och Elekta har ca 10-15% av aktierna blankade idag.

Larry Leksell är en passionerad konstsamlare med hundratals konstobjekt i sin samling. Som i så många andra fall inleddes hans konstsamlande med att han köpte grafik. Han har startat Leksell Social Ventures som är ett investeringsbolag som fokuserar på inkludering av utlandsfödda, psykisk ohälsa och tekniklösningar för social samhällsnytta. Larry Leksell är huvudägare och styrelseledamot i Elekta och tidigare ordförande i Stadsmissionen under 10 år. Vi pratar om samtidskonst och samlande, uppväxt, samhällsengagemang och vikten av mångfald. Som vanligt resonerar vi om hur vi skall bygga upp vår nya verksamhet i Södertälje och får väldigt bra input.

This week on Hey You Geeks, we’re putting our casting director hats on to make our picks for the actors we'd most like to see play a young Han Solo in the just announced Han Solo anthology film to be directed by Christopher Miller and Phil Lord (The Lego Movie) and written by Lawrence and Jon Kasdan. We're also talking about the casting of Elodie Yung as Elekta in the Netflix Daredevil series,the second season premiere of Star Wars Rebels, Terminator Genisys and the fan film culture and the first images to emerge from Paul Feig's Ghostbusters. Enjoy the show...

I det här avsnittet av Fill or Kill diskuteras Fingerprint, Elekta, Neurovive och omviktningar i MSCI SBX och dom hetaste twitteryktena. Utöver det får vi höra en het diskussion om det senaste gällande Greklandskrisen.

Minusränta, Elekta och fastigheter snackas det om i veckans avsnitt. John presenterar även sin topp 3-lista bland norska bolag.

Med Alex Schulman och Martin Gärtner Att skänka en slant till välgörenhet, träna barnens fotbollslag, nattvandra eller att förse entreprenörer med riskkapital. Utan ett ideellt engagemang skulle vi inte ha ett fungerande samhälle. Martin Gärtner, global chef för Private Banking samtalar med Laurent Leksell, huvudägare i Elekta och styrelseordförande i Stockholms Stadsmission, om filantropi. See acast.com/privacy for privacy and opt-out information.